Shanghai Virogin Biotech

Virogin Biotech is a clinical-stage biotechnology company specializing in the development of next-generation oncolytic viruses and synergistic immunotherapies for the treatment of cancer. The company utilizes its proprietary Synerlytic platform to engineer highly potent oncolytic Herpes Simplex Virus-1 (oHSV-1) vectors that not only selectively kill tumor cells but also stimulate a robust systemic anti-tumor immune response. Their lead candidate, VG161, is currently in Phase 2 clinical trials, demonstrating the company's ability to transition innovative viral engineering into clinical applications. With a dual presence in Shanghai and Vancouver, Virogin is positioned as a global leader in the oncolytic virus space, focusing on high-unmet-need indications such as advanced solid tumors and liver cancers.